CCL13 and ovarian carcinoma: The positive and high expression rates of MCP-4 in the ovarian cancer group (91.43% (96/105) and 75.24% (26/105)) were significantly higher than those in the borderline group (57.14% (12/21) and 19.05% (4/21)) (both P < 0.05), benign group (41.67% (5/12) and 8.33% (1/12)) (both P < 0.05), and normal ovarian tissues (44.44% (4/9) and 0.00% (0/9)) (both P < 0.05) (Table 1).